Get access to our best features
Get access to our best features
Published 2 months ago

FDA says it needs more research before deciding to approve nasal spray to treat dangerous allergies

Summary by Ground News
The U.S. Food and Drug Administration told ARS Pharmaceuticals Inc., of San Diego, that the company needs to conduct another study on repeat doses of epinephrine. The move comes four months after an FDA advisory committee recommended approval of the device, dubbed neffy. The company will appeal the FDA's decision and resubmit an application in early 2024.
More
Filters

15 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 58% of the sources are Center
67% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics